Paolo Tarantino: The highly debated results of PALOMA2 now published on JCO

Paolo Tarantino, Medical Oncologist, PhD Università degli Studi di Milano, Research Dana-Farber Cancer Institute, Harvard University, shared a post on X/Twitter:

“The highly debated results of PALOMA2 now published on JCO: the addition of palbociclib to 1L letrozole did not improve OS in HR+ MBC. The reason for the discrepancy with ribociclib and  abemaciclib data remains unclear. Ultimately led to a reduction in the use of palbociclib.”

View additional information.
Source: Paolo Tarantino/X